Nurix Therapeutics to Participate in Upcoming Investor Conferences
09 mars 2022 16h01 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, March 09, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T....
Nurix Therapeutics to Present Preclinical Data from Its Novel BTK Degrader (NX-2127) and CBL-B Inhibitor (NX-0255) Programs at the American Association for Cancer Research Annual Meeting
08 mars 2022 16h47 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical...
Nurix Therapeutics Announces Participation in the 11th Annual SVB Leerink Global Healthcare Conference
10 févr. 2022 16h01 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T....
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update
27 janv. 2022 16h01 HE
|
Nurix Therapeutics, Inc.
Advanced four wholly owned and internally developed programs into clinical development Strengthened balance sheet with year-end cash and investments totaling $433 million Anticipate multiple...
Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts
10 janv. 2022 07h00 HE
|
Nurix Therapeutics, Inc.
Nurix leads protein modulation field with four active clinical stage programs Anticipates data-rich 2022 with clinical-stage programs and a pipeline fueled by proprietary DELigase platform ...
Nurix Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
03 janv. 2022 16h01 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T....
Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting
12 déc. 2021 09h00 HE
|
Nurix Therapeutics, Inc.
U.K. regulatory authorities grant Clinical Trial Authorization with dosing of first patient anticipated in the first half of 2022 NX‑5948 crosses the blood‑brain barrier in preclinical models...
Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors
12 nov. 2021 07h09 HE
|
Nurix Therapeutics, Inc.
Food and Drug Administration clears DeTIL-0255 to initiate Phase 1 clinical trial Phase 1 clinical trial initiation anticipated by year-end 2021 SAN FRANCISCO, Nov. 12, 2021 (GLOBE NEWSWIRE) --...
Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC Conference
12 nov. 2021 07h07 HE
|
Nurix Therapeutics, Inc.
DeTIL-0255 is a drug-enhanced investigational new cell therapy product candidate with potentially superior T cell properties compared to conventional TIL Michael T. Lotze, Nurix’s chief cellular...
Nurix Therapeutics to Participate in Upcoming Investor Conferences
09 nov. 2021 16h01 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T....